Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
In France, since 1988, factor VIII concentrate are prepared by ion exchanged chromatography from plasma cryoprecipitate. The final product is a very high purity factor VIII with a specific activity (SA) between 150 and 250 IU/mg of proteins. Viral inactivation is obtained after solvent detergent method with TNBP and Tween 80. Since 1989 hemophilia B patients are treated with a factor IX preparation purified from a prothrombin complex concentrate and after solvent detergent inactivation. Factor IX concentrate is a high purity product with a SA of 50 to 100 U/mg of protein.
Sultan
Y
Y
Centre des Hémophiles, Hôpital Cochin, Paris, France.
Boyeldieu
D
D
Stieltjes
N
N
D002852:Chromatography, Ion Exchange; D005164:Factor IX / Q000302:isolation & purification / Q000627:therapeutic use*; D005169:Factor VIII / Q000302:isolation & purification / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy*; D002836:Hemophilia B / Q000188:drug therapy*; D006801:Humans
D005169:Factor VIII; D005164:Factor IX